Jamie Reynoso Amends Form 4: RSU Vesting Led to $1.23/Share Withholding
Rhea-AI Filing Summary
Jamie L. Reynoso, an officer (CEO, Medicare Advantage) of Clover Health Investments (CLOV), amended a Form 4 to clarify equity movements tied to performance-based restricted stock units (RSUs). The amendment confirms that 52,967 shares of Class A common stock were disposed of on 06/30/2024 at a price of $1.23 per share to satisfy tax withholding related to the vesting of the second tranche of performance-based RSUs. The RSUs were awarded March 16, 2023, with one-third vested September 7, 2023, one-third on June 30, 2024, and the final third scheduled for June 30, 2025. Following the transaction, the reporting person directly holds 2,401,108 Class A shares.
Positive
- Clarified disclosure of the RSU withholding enhances transparency about insider equity changes
- Performance-based RSU structure vests over multiple years (2023–2025), aligning executive compensation with longer-term performance
Negative
- Automatic disposition of 52,967 shares reduced the reporting person’s immediate share count
- Sale price $1.23 indicates shares were transferred at a low per-share amount for tax withholding purposes
Insights
TL;DR: Routine RSU vesting triggered tax-withholding share disposition; transaction is operational, not a directional bet on CLOV stock.
The amendment clarifies that the reported disposition of 52,967 shares at $1.23 per share reflects automatic withholding to cover tax obligations arising from the vesting of performance-based RSUs. This is a common administrative step when equity awards vest and does not necessarily indicate a decision to liquidate for cash beyond tax obligations. The reported remaining direct holdings of 2,401,108 shares provide context for the insider's stake size.
TL;DR: Disclosure amendment improves transparency on executive compensation realization and tax treatment.
Filing an amendment to clarify the composition and tax withholding related to earned performance-based RSUs strengthens disclosure quality. The schedule of vesting (one-third increments across 2023–2025) ties executive reward to multi-year performance, which aligns incentives with longer-term shareholder interests. The transaction code and price are disclosed, meeting Section 16 transparency requirements.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Class A Common Stock | 52,967 | $1.23 | $65K |
Footnotes (3)
- F1. This Form 4/A is being filed to solely to clarify that the total number of restricted stock units (RSUs) received upon determination of the level of performance-based RSU grant was previously reported by the Reporting Person on a Form 4/A, filed on January 3, 2024, as described in Footnote 2 below.
- F2. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations due to the vesting of the second tranche of the number of earned restricted stock units, as described herein. Represents restricted stock units, each representing a right to a share of Class A Common Stock, earned in connection with the determination of the level of performance achievement in satisfaction of vesting conditions underlying a performance-based restricted share unit grant awarded on March 16, 2023. One-third of the number of earned restricted stock units vested on September 7, 2023, one-third of the number of earned restricted stock units vested on June 30, 2024, and the remaining one-third of the earned restricted stock units vested on June 30, 2025.
- F3. Number reflects total directly held Class A Common Stock taking into account the amended number and transactions through June 30, 2024.
AI-generated analysis. How Rhea-AI works. Not financial advice.
